Folic Acid and Vitamin B6, B12 Supplements do not offer Lowered Cancer Risk

Researchers at Brigham and Women's Hospital and Harvard Medical School have found that supplements of folic acid, vitamins B6 and B12 neither reduce nor increase the risk of breast or other invasive cancers in women.

Experimental Drug Burns Fat Even on a High-Fat Diet

A team of French scientists has said that they have discovered a fat burning drug that "tricks the body into burning off fat," even while on a high fat diet. The drug, called SRT1720 has so far only been successfully tested on mice by a team of scientists at the University of Louis Pasteur.

Mylan gets nod to market UCB’s epilepsy drug

Mylan Inc., the biggest US maker of generic drugs, has informed that it has received approval to market a generic version of Levetiracetam Tablets.

The company said that Food and Drug Administration has approved its application to market generic versions of the drug, also called Levetiracetam, in 250 milligram, 500 mg and 750 mg tablets.

Levetiracetam Tablets are the generic version of UCB Pharma's Keppra, which is indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy.

Cardiovascular System to merge with Replidyne

Cardiovascular Systems Inc. (CSI) has entered into a definitive merger agreement under which CSI will merge with Struggling biotech company Replidyne Inc in an all-stock merger valued at up to $40 million.

CSI is a medical device company focused on developing and commercializing interventional treatment systems for vascular disease.

Genzye Corp inks alliance with Orisis Therapeutics

Genzye Corp. has signed a stem cell treatment development and sales deal with stem cell company Orisis Therapeutics to develop two new treatments.

Under the deal, Genzyme will make an upfront $130 million payment to Osiris for rights to the company's developing Prochymal and Chondrogen treatments.

An official release stated that Osiris would commercialize both drugs in the U.S. and Canada, while Genzyme would have sales rights in all other countries.

Apart from this, Osiris could receive up to $1.25 billion in milestone payments, based on the drugs' development and eventual sales.

Pages

Most Popular

Beyond Meat Stock Surges on Wall Street

Beyond Meat recently debuted in the stock market and the company making plant-based meat has received strong response from investors in the stock market.

Co-working spaces company WeWork plans to go Public this year

WeWork, the company that provides shared working places for freelancers, start-ups and large enterprises, is considering going public this year.

Hyundai Motors starts production of new Kona Electric CUV

According to reports, a noteworthy first batch of the new Kona Electric compact CUV has been produced by South Korean automaker Hyundai, and export of the vehicle have also been

Toyota showcases second-gen zero-emissions Class 8 electric truck

In a move which marks the launch of Toyota’s second-generation zero-emissions, hydrogen fuel cell Class 8 electric truck, the automaker has recently unveiled Kenworth T680 proto

Ford announces $4 billion investment in autonomous vehicle venture

In a move which will enable US automaker Ford to gain a competitive edge in the newly emerging mobility industry, the automaker has recently launched a new autonomous vehicle su